Astellas Pharma EMEA appoints new chief financial officer
pharmafile | September 17, 2015 | Appointment | Sales and Marketing | Astellas, Eugene Van Rensburg
Astellas Pharma Europe, Middle East and Africa has appointed Eugene Van Rensburg to the position of chief financial officer, from his previous role as senior finance director.
Van Rensburg succeeds Niek Stander, who will now head up the company’s German operations as managing director of Astellas Pharma GmbH.
Van Rensburg has over 15 years of industry experience. As chief financial officer, he will oversee the finance function across 40 countries in the region. He will have responsibility for all financial planning and operations, as well as tax, treasury, procurement and information systems. As the company moves forward, his main priority will be to focus on strategic planning and budgeting, cost and process optimisation, profitability analysis and innovative ways to maximise the value of existing brands and assets.
He comments: “It is an exciting time to be a trusted advisor and part of the leadership team at Astellas. Our company is building on existing areas of excellence, such as our franchises in urology, oncology and transplantation, by proactively seeking novel technologies and new opportunities in different therapeutic areas. We’ve recently launched three new classes of treatment in the EMEA region, and with eight therapies in late stage development, Astellas has a unique platform for continued growth.”
Ken Jones, president and chief executive of Astellas Pharma EMEA, comments: “Eugene will play a major role as we work to sustain this success, by maximising the value of our portfolio, prioritising research and development, and achieving operational excellence.”
Related Content
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …
EMA accepts Astellas’ MAA for Zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing …
Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …
